Ozempic Gastroparesis: Understanding the Risk Factors for Monitoring

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specific Drug Risks

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal discomfort, you may be wondering about the risk of gastroparesis. Decades of pharmacovigilance have established that certain medications can slow gastric emptying, and recent research has focused on GLP-1 receptor agonists like semaglutide. This page explains who may need closer monitoring and what the science says about diagnosis and risk factors.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Among its known adverse effects, gastrointestinal (GI) reactions are prominent and have been linked to the development of gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, the pharmacological profile of Ozempic, mechanistic pathways connecting the drug to gastroparesis, and settlement-related considerations for affected patients. Clinical Presentation and Diagnosis of Gastroparesis: Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate of solid food emptying from the stomach. The condition can lead to malnutrition, dehydration, and impaired quality of life. In the context of Ozempic use, these symptoms may overlap with common GI adverse reactions reported in clinical trials. For instance, in placebo-controlled trials, GI adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, specific GI adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in GI symptoms, which may mimic or exacerbate gastroparesis.

Pharmacology and Reported Adverse Effects of Ozempic

Ozempic works by activating GLP-1 receptors, which stimulate insulin secretion, suppress glucagon release, and slow gastric emptying. This delay in gastric emptying is a therapeutic mechanism for glycemic control but can become pathological when excessive or prolonged. The drug's labeling acknowledges that GI adverse reactions are common, with 3.1% of patients on Ozempic 0.5 mg and 3.8% on Ozempic 1 mg discontinuing treatment due to these reactions, compared to 0.4% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, GI adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These findings suggest a dose-response relationship, which is relevant for assessing risk of gastroparesis.

Mechanistic Pathways Linking Ozempic to Gastroparesis

The primary mechanism linking Ozempic to gastroparesis is its effect on gastric motility. GLP-1 receptor agonists inhibit gastric emptying by relaxing the proximal stomach and contracting the pylorus, leading to delayed transit of food. In susceptible individuals, this effect can become sustained, resulting in gastroparesis. Additionally, the drug may cause inflammation or autonomic dysfunction, though these pathways are less established. The labeling does not explicitly list gastroparesis as an adverse reaction, but the high rates of nausea, vomiting, and dyspepsia—symptoms that overlap with gastroparesis—suggest a potential link. The absence of a specific warning for gastroparesis in the labeling is a key risk anchor.

Adequacy of Warnings Regarding Ozempic and Gastroparesis

The current labeling for Ozempic includes warnings about serious hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported with other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no explicit warning about gastroparesis. The GI adverse reactions section describes common symptoms but does not differentiate between transient effects and chronic conditions like gastroparesis. This lack of specificity may be considered inadequate for patients who develop persistent symptoms. The labeling advises caution in patients with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but no similar guidance exists for GI complications.

Settlement-Related Considerations for Affected Patients

For patients who develop gastroparesis after using Ozempic, settlement considerations may include the timing of symptom onset relative to drug initiation, the duration of use, and the presence of other risk factors. The evidence shows that GI adverse reactions often occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting a temporal relationship. Patients who experienced persistent nausea, vomiting, or abdominal pain after starting Ozempic and were later diagnosed with gastroparesis may have a basis for a claim. The lack of a specific warning could be argued as a failure to adequately inform patients and healthcare providers of the risk. Settlement criteria would likely require documented evidence of gastroparesis diagnosis, a timeline linking Ozempic use to symptom onset, and exclusion of other causes.

Timeline Between Exposure and Documented Harm

The timeline between Ozempic exposure and gastroparesis is critical for establishing causation. Clinical trial data indicate that GI adverse reactions are most common during the initial dose escalation period, typically within the first few weeks of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis may develop later, after prolonged use. Patients who discontinue Ozempic due to GI symptoms may still experience delayed gastric emptying that persists after drug cessation. The labeling does not provide data on the duration of GI effects after discontinuation, which complicates the timeline assessment. For settlement purposes, a clear temporal association—such as symptom onset within weeks of starting Ozempic and a diagnosis of gastroparesis confirmed by gastric emptying scintigraphy—would strengthen a claim.

Conclusion

The evidence from clinical trials demonstrates a dose-dependent increase in GI adverse reactions with Ozempic, including symptoms that overlap with gastroparesis. The mechanistic link through delayed gastric emptying is plausible, but the labeling lacks a specific warning for gastroparesis. Patients who develop this condition may have grounds for settlement if they can establish a temporal relationship and exclude other causes. Healthcare providers should monitor for persistent GI symptoms and consider gastroparesis as a potential adverse effect.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. In some patients, this effect can become excessive or prolonged, leading to gastroparesis—a condition of delayed gastric emptying without mechanical obstruction. Clinical trials show dose-dependent increases in GI adverse reactions such as nausea, vomiting, and dyspepsia, which overlap with gastroparesis symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic gastroparesis lawsuits?

Settlement criteria typically require documented evidence of a gastroparesis diagnosis (e.g., via gastric emptying scintigraphy), a clear temporal relationship between Ozempic use and symptom onset (often within weeks of starting or dose escalation), and exclusion of other causes. The lack of a specific warning about gastroparesis in the drug labeling may strengthen claims (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does Ozempic's labeling warn about gastroparesis?

No, the current labeling for Ozempic does not explicitly warn about gastroparesis. It lists common GI adverse reactions but does not differentiate between transient effects and chronic conditions like gastroparesis. This lack of specificity may be considered inadequate for patients who develop persistent symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.